Patents by Inventor Alex R. Zelenchuk
Alex R. Zelenchuk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140127137Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.Type: ApplicationFiled: June 17, 2013Publication date: May 8, 2014Applicant: Cercacor Laboratories, IncInventors: Emile M. Bellott, Dongsheng Bu, James J. Childs, Christopher Lambert, Hubert A. Nienaber, Shirley J. Shi, Zhaolin Wang, Jerome J. Workman, Alex R. Zelenchuk
-
Patent number: 8466286Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.Type: GrantFiled: August 22, 2011Date of Patent: June 18, 2013Assignee: Cercacor Laboratories, Inc.Inventors: Emile M. Bellott, Dongsheng Bu, James J. Childs, Christopher Lambert, Hubert A. Nienaber, Shirley J. Shi, Zhaolin Wang, Jerome J. Workman, Alex R. Zelenchuk
-
Patent number: 8311607Abstract: A system and method for the in situ discrimination of healthy and diseased tissue. A fiberoptic based probe is employed to direct ultraviolet illumination onto a tissue specimen and to collect the fluorescent response radiation. The response radiation is observed at three selected wavelengths, one of which corresponds to an isosbestic point. In one example, the isosbestic point occurs at about 431 nm. The intensities of the observed signals are normalized using the 431 nm intensity. A score is determined using the ratios in a discriminant analysis. The tissue under examination is resected or not, based on the diagnosis of disease or health, according to the outcome of the discriminant analysis.Type: GrantFiled: August 22, 2011Date of Patent: November 13, 2012Assignee: Luma Imaging CorporationInventor: Alex R. Zelenchuk
-
Publication number: 20120052018Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.Type: ApplicationFiled: August 22, 2011Publication date: March 1, 2012Applicant: Masimo Laboratories, Inc.Inventors: Emile M. Bellott, Dongsheng Bu, James J. Childs, Christopher Lambert, Hubert A. Nienaber, Shirley J. Shi, Zhaolin Wang, Jerome J. Workman, Alex R. Zelenchuk
-
Publication number: 20120046554Abstract: A system and method for the in situ discrimination of healthy and diseased tissue. A fiberoptic based probe is employed to direct ultraviolet illumination onto a tissue specimen and to collect the fluorescent response radiation. The response radiation is observed at three selected wavelengths, one of which corresponds to an isosbestic point. In one example, the isosbestic point occurs at about 431 nm. The intensities of the observed signals are normalized using the 431 nm intensity. A score is determined using the ratios in a discriminant analysis. The tissue under examination is resected or not, based on the diagnosis of disease or health, according to the outcome of the discriminant analysis.Type: ApplicationFiled: August 22, 2011Publication date: February 23, 2012Applicant: LUMA IMAGING CORPORATIONInventor: Alex R. Zelenchuk
-
Patent number: 8029765Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.Type: GrantFiled: December 23, 2004Date of Patent: October 4, 2011Assignee: Masimo Laboratories, Inc.Inventors: Emile M. Bellott, Dongsheng Bu, James J. Childs, Christopher Lambert, Hubert A. Nienaber, Shirley J. Shi, Zhaolin Wang, Jerome J. Workman, Alex R. Zelenchuk
-
Patent number: 8008088Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.Type: GrantFiled: June 26, 2006Date of Patent: August 30, 2011Assignee: Masimo Laboratories, Inc.Inventors: Emile M. Bellott, Dongsheng Bu, James J. Childs, Christopher Lambert, Hubert A. Nienaber, Shirley J. Shi, Zhaolin Wang, Jerome J. Workman, Alex R. Zelenchuk
-
Patent number: 8005527Abstract: A system and method for the in situ discrimination of healthy and diseased tissue. A fiberoptic based probe is employed to direct ultraviolet illumination onto a tissue specimen and to collect the fluorescent response radiation. The response radiation is observed at three selected wavelengths, one of which corresponds to an isosbestic point. In one example, the isosbestic point occurs at about 431 nm. The intensities of the observed signals are normalized using the 431 nm intensity. A score is determined using the ratios in a discriminant analysis. The tissue under examination is resected or not, based on the diagnosis of disease or health, according to the outcome of the discriminant analysis.Type: GrantFiled: December 12, 2007Date of Patent: August 23, 2011Assignee: Luma Imaging CorporationInventor: Alex R. Zelenchuk
-
Patent number: 7831298Abstract: Systems, apparatus and techniques for non-invasive optical probing of various substances, and systems, apparatus and techniques for detecting, diagnosing and treating a disease in lungs and other organs using the non-invasive optical probing, including mapping physiological functions of tissues in lungs and other organs.Type: GrantFiled: May 11, 2007Date of Patent: November 9, 2010Assignee: Tomophase CorporationInventors: Feiling Wang, Alex R. Zelenchuk, Xiao-Li Li
-
Publication number: 20090004108Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.Type: ApplicationFiled: December 23, 2004Publication date: January 1, 2009Applicant: Masimo Laboratories, Inc.Inventors: Emile M. Bellott, Dongsheng Bu, James J. Childs, Christopher Lambert, Hubert A. Nienaber, Shirley J. Shi, Zhaolin Wang, Jerome J. Workman, Alex R. Zelenchuk
-
Patent number: 7310547Abstract: A system and method for the in situ discrimination of healthy and diseased tissue. A fiberoptic based probe is employed to direct ultraviolet illumination onto a tissue specimen and to collect the fluorescent response radiation. The response radiation is observed at three selected wavelengths, one of which corresponds to an isosbestic point. In one example, the isosbestic point occurs at about 431 nm. The intensities of the observed signals are normalized using the 431 nm intensity. A score is determined using the ratios in a discriminant analysis. The tissue under examination is resected or not, based on the diagnosis of disease or health, according to the outcome of the discriminant analysis.Type: GrantFiled: July 19, 2004Date of Patent: December 18, 2007Assignee: Medispectra, Inc.Inventor: Alex R. Zelenchuk
-
Patent number: 7225005Abstract: A system and method for determining an in vivo property of a tissue or blood is described. The in vivo property may be a hematocrit value, a hemoglobin concentration, or a combination thereof. The system can automatically determine a location of a subcutaneous blood vessel. Based on the automatically determined location, the system illuminates the blood vessel with a light beam and detects light resulting from the illumination. The system determines the in vivo property based on the detected light. Alternatively, or in combination, the system displays an image corresponding to a spatial relationship between a subcutaneous blood vessel and a light beam. Based on the image, an operator can adjust the light beam with respect to the blood vessel to have a selected spatial relationship. The system determines an in vivo property based on the illumination of the blood vessel when the light beam has the selected spatial relationship.Type: GrantFiled: December 14, 2004Date of Patent: May 29, 2007Assignee: Intelligent Medical Devices, Inc.Inventors: Howard B. Kaufman, Alex R. Zelenchuk
-
Patent number: 7103401Abstract: A system and method for the in situ discrimination of healthy and diseased tissue. A fiberoptic based probe is employed to direct ultraviolet illumination onto a tissue specimen and to collect the fluorescent response radiation. The response radiation is observed at three selected wavelengths, about 403 nm, about 414 nm, and about 431 nm. The intensities of the 403 nm and 414 mn radiation are normalized using the 431 nm intensity. A score is determined using the ratios in a linear discriminant analysis (LDA). The tissue under examination is resected or not, based on the outcome of the LDA.Type: GrantFiled: July 10, 2002Date of Patent: September 5, 2006Assignee: MediSpectra, Inc.Inventors: Kevin T. Schomacker, Norman S. Nishioka, Alex R. Zelenchuk
-
Patent number: 6768918Abstract: A system and method for the in situ discrimination of healthy and diseased tissue. A fiberoptic based probe is employed to direct ultraviolet illumination onto a tissue specimen and to collect the fluorescent response radiation. The response radiation is observed at three selected wavelengths, one of which corresponds to an isosbestic point. In one example, the isosbestic point occurs at about 431 nm. The intensities of the observed signals are normalized using the 431 nm intensity. A score is determined using the ratios in a discriminant analysis. The tissue under examination is resected or not, based on the diagnosis of disease or health, according to the outcome of the discriminant analysis.Type: GrantFiled: July 10, 2002Date of Patent: July 27, 2004Assignee: MediSpectra, Inc.Inventor: Alex R. Zelenchuk
-
Publication number: 20040010195Abstract: A system and method for the in situ discrimination of healthy and diseased tissue. A fiberoptic based probe is employed to direct ultraviolet illumination onto a tissue specimen and to collect the fluorescent response radiation. The response radiation is observed at three selected wavelengths, one of which corresponds to an isosbestic point. In one example, the isosbestic point occurs at about 431 nm. The intensities of the observed signals are normalized using the 431 nm intensity. A score is determined using the ratios in a discriminant analysis. The tissue under examination is resected or not, based on the diagnosis of disease or health, according to the outcome of the discriminant analysis.Type: ApplicationFiled: July 10, 2002Publication date: January 15, 2004Inventor: Alex R. Zelenchuk
-
Publication number: 20040010187Abstract: A system and method for the in situ discrimination of healthy and diseased tissue. A fiberoptic based probe is employed to direct ultraviolet illumination onto a tissue specimen and to collect the fluorescent response radiation. The response radiation is observed at three selected wavelengths, about 403 nm, about 414 nm, and about 431 nm. The intensities of the 403 nm and 414 mn radiation are normalized using the 431 nm intensity. A score is determined using the ratios in a linear discriminant analysis (LDA). The tissue under examination is resected or not, based on the outcome of the LDA.Type: ApplicationFiled: July 10, 2002Publication date: January 15, 2004Inventors: Kevin T. Schomacker, Norman S. Nishioka, Alex R. Zelenchuk